LUZMILA VIA: Open Payments
NPI 1740979251 · RIDGEWAY, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$415 in 23 payments from 12 companies in 2025. Trend: 2023 $45 · 2024 $265 · 2025 $415
Food & beverage: $415
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $73 |
| AstraZeneca Pharmaceuticals LP | 4 | $68 |
| ANI Pharmaceuticals, Inc. | 2 | $44 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $38 |
| Ardelyx, Inc. | 2 | $37 |
| Gilead Sciences, Inc. | 2 | $36 |
| Travere Therapeutics, Inc. | 2 | $22 |
| ABBVIE INC. | 1 | $21 |
| Dexcom, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
Products named: PURIFIED CORTROPHIN GEL, FARXIGA, Kerendia, IBSRELA, Ozempic, QULIPTA, Dexcom G6 Transmitter, VOYXACT.
Industry payments across VA — which companies pay providers there.
